Selskabets formål er at drive forskning, handel, fabrikation og dermed beslægtet virksomhed primært inden for sundhedssektoren.
| Year | Revenue | Profit/Loss | Total Assets | Equity | Employees | Report |
|---|---|---|---|---|---|---|
| 2025 | 40.3 mio. | -81.4 mio. | 24.8 mio. | -837.6 mio. | 26 | |
CVR: 18645882
Secondary names: DIAGNOSTICK A/S, ANTIBODYSHOP A/S
Previous names: SCSK 1868 ApS, RØNNEVANGSCENTRET ApS, IDEGO ApS
Compared to 997 companies in Forskning og eksperimentel udvikling inden for naturvidenskab og teknik
Comparison is based on industry median values
Klaus Juhl Wulff joined the board
Niels Jørgen Høy Nielsen left the board
Carsten Buhl joined the board
Peter Mørch Eriksen left the board
Carsten Buhl joined as ADM. DIR.
Peter Mørch Eriksen left as ADM. DIR.
The financial health of BIOPORTO DIAGNOSTICS A/S is concerning, characterized by consistent losses and negative equity over the past five years. Revenue has shown a gradual increase from 24.25 million DKK in 2021 to 40.29 million DKK in 2025, yet profits remain deeply negative, with a loss of 81.4 million DKK in 2025. The company's equity has deteriorated significantly, falling to -837.6 million DKK, indicating substantial financial strain and potential solvency issues. While revenue growth suggests some operational progress, the persistent losses and declining equity position raise significant concerns about its long-term viability within the research and experimental development sector.
AI-generated summary
Companies in the same industry and area
companydata.dk